Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01586689 · ClinicalTrials.gov registry record · Phase 2
Evaluating Alternative Aftercare Models for Ex-offenders
A Phase 2 study of Drug/Substance Abuse/Addiction and Alcohol Abuse/Addiction, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT01586689: Completed Phase 2 study of Drug/Substance Abuse/Addiction and Alcohol Abuse/Addiction, sponsored by National Institute on Drug Abuse (NIDA).
NCT01586689 is a Phase 2 study of Drug/Substance Abuse/Addiction and Alcohol Abuse/Addiction that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 270 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (103% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01586689, a Phase 2 study of Drug/Substance Abuse/Addiction and Alcohol Abuse/Addiction, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is examining the relative effects of alternative aftercare models for ex-offenders who are recovering from substance abuse/addiction. The study is a longitudinal, randomized field trial that assigns participants to one of three conditions: Oxford House, a professionally-run residential treatment facility, or a control condition that involves usual aftercare chosen by participants (which may include no treatment at all). Oxford Houses are self-run residential recovery homes based on the premise of mutual support. These homes do not involve professional treatment staff and the expenses (e.g. rent, utilities) are paid for by the residents. The hypothesis of this study is that Oxford House participants will have as good or better outcomes in terms of substance recovery, recidivism, and health in comparison to the participants who were assigned to the residential treatment facility, and better outcomes in comparison to the control group. In addition, the cost to government/tax payers will be substantially lower given that participants pay their own way.
Primary Outcome
An assessment of each participant's drug/alcohol use as determined by a urine test and report of alcohol use
Conditions Studied
Interventions
- BEHAVIORAL Oxford House
- BEHAVIORAL Safe Haven
- BEHAVIORAL Usual aftercare
Study Locations (1)
Illinois
- DePaul University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT01586689 record still lists
NCT01586689 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (103% higher).
The record links to 2 conditions, with Drug/Substance Abuse/Addiction appearing as the primary indexed condition, and to 3 interventions - of which Oxford House is the first listed.
NCT01586689 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01586689 about?
NCT01586689 is a clinical study titled "Evaluating Alternative Aftercare Models for Ex-offenders". This study is examining the relative effects of alternative aftercare models for ex-offenders who are recovering from substance abuse/addiction. The study is a longitudinal, randomized field trial that assigns participants to one of three conditions: Oxford House, a professionally-run residential tr...
What is the current status of trial NCT01586689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2006-09. Estimated completion is 2013-06.
What conditions does trial NCT01586689 study?
This clinical trial studies the following conditions: Drug/Substance Abuse/Addiction, Alcohol Abuse/Addiction.
What interventions are being tested in trial NCT01586689?
The interventions under investigation include: Oxford House (BEHAVIORAL), Safe Haven (BEHAVIORAL), Usual aftercare (BEHAVIORAL).
Who is sponsoring clinical trial NCT01586689?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01586689 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01586689's enrollment target sits among peer trials
270 205th of 2000 higher than 1,793 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia